NCT05451602View on ClinicalTrials.gov

HEC169096 in Participants With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

456

Participants

Timeline

Start Date

October 21, 2022

Primary Completion Date

July 30, 2025

Study Completion Date

August 30, 2027

Conditions
Advanced Solid Tumor
Interventions
DRUG

HEC169096

Multiple doses of HEC169096 during Phase 2；Oral dose of HEC169096 as determined during Phase 2.

Trial Locations (1)

Unknown

RECRUITING

GuangDong Province Peoples Hospital, Guangzhou

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY